Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 151

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 151
---
 to the clinic in 12-18 months. Following the meeting, Aadi’s management team evaluated over 20 ADC companies and 40 ADC assets against the designated criteria and prioritized ADC
portfolios from five companies, including Wuxi Biologics, for further due diligence analysis.

On July 12, 2024, Aadi received access to the dataroom
of WuXi Biologics and commenced due diligence.

On July 17, 2024, representatives of Aadi, WuXi Biologics and Hangzhou DAC met via videoconference to
discuss the CPT113 linker-payload platform developed by Hangzhou DAC as well as the MUC16 ADC asset.

On July 18, 2024, representatives of Aadi and
WuXi Biologics met via video conference to discuss a potential transaction and discussed a potential in-license of the PTK7-CPT113 asset on a stand-alone basis.

On July 23, 2024, the Strategic Transaction Committee held a meeting to discuss strategic opportunities with Aadi’s management team. At the meeting,
the committee deliberated with Aadi’s management team regarding the potential in-license of PTK7-CPT113 as a stand-alone asset and determined not to pursue that opportunity.

On July 25, 2024, representatives of Aadi communicated to representatives of WuXi Biologics that Aadi was not interested in licensing PTK7-CPT113 as a
stand-alone asset. However, following discussion with Aadi’s business development consultant, on August 1, 2024, representatives of Aadi contacted representatives of WuXi Biologics to explore the possibility of licensing a multi-asset ADC
portfolio to compensate for the preclinical stage of the assets. Based on the criteria for validating ADC targets established by the Strategic Transaction Committee, Aadi’s management team centered in on three assets of WuXi Biologics,
targeting each of PTK7, MUC16 and SEZ6. Given that the preclinical status of these programs and length of time to clinical trials would be critical to understanding value, representatives of Aadi engaged in discussions with Wuxi Biologics to
determine the specific status of each program and determine timing to human clinical studies, and to assess the likelihood of delivering these programs to human trials in the timeline preferred by Strategic Transaction Committee.

On August 6, 2024, the Strategic Transaction Committee held a meeting to discuss strategic opportunities with Aadi’s management team. At